New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 24, 2014
16:13 EDTTSROTESARO reports Q2 EPS ($1.03), consensus (87c)
TESARO anticipates achieving the following key objectives during the second half of 2014: Submit the oral rolapitant New Drug Application to the FDA in approximately six weeks; Initiate a clinical trial of IV rolapitant to support the planned future NDA submission for registration following regulatory approval of oral rolapitant; Continue to advance the Phase 3 NOVA trial of niraparib as a maintenance therapy for patients with ovarian cancer and the Phase 3 BRAVO trial of niraparib in breast cancer patients with germline BRCA mutations; Advance the TSR-011 controlled release formulation work and further evaluate the clinical activity of a fractionated dose of TSR-011 in ALK-positive and TRK-positive patients.
News For TSRO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 20, 2014
07:51 EDTTSROTESARO, Myriad Genetics announce companion diagnostics collaboration
Subscribe for More Information
November 19, 2014
07:09 EDTTSROJefferies to hold a conference
2014 Global London Healthcare Conference is being held in London, England on November 19-20.
November 12, 2014
11:17 EDTTSROLeerink major pharma & biotech analysts hold analyst/industry conference call
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use